Insmed Incorporated (NASDAQ:INSM) COO Sells $132,990.00 in Stock

Insmed Incorporated (NASDAQ:INSM - Get Free Report) COO Roger Adsett sold 1,860 shares of Insmed stock in a transaction on Tuesday, June 3rd. The stock was sold at an average price of $71.50, for a total transaction of $132,990.00. Following the transaction, the chief operating officer now owns 141,323 shares in the company, valued at $10,104,594.50. This represents a 1.30% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Roger Adsett also recently made the following trade(s):

• On Wednesday, May 14th, Roger Adsett sold 1,925 shares of Insmed stock. The stock was sold at an average price of $65.61, for a total transaction of $126,299.25.
• On Tuesday, May 13th, Roger Adsett sold 7,482 shares of Insmed stock. The shares were sold at an average price of $67.81, for a total transaction of $507,354.42.

Insmed Stock Performance

INSM stock traded up $0.88 during trading on Friday, hitting $73.62. 1,558,246 shares of the company's stock traded hands, compared to its average volume of 2,072,473. The stock has a market capitalization of $13.41 billion, a price-to-earnings ratio of -13.17 and a beta of 0.80. The stock has a fifty day moving average price of $69.28 and a two-hundred day moving average price of $73.04. Insmed Incorporated has a 52 week low of $55.74 and a 52 week high of $84.91. The company has a quick ratio of 5.99, a current ratio of 6.37 and a debt-to-equity ratio of 2.03.

Insmed (NASDAQ:INSM - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($1.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.36) by ($0.06). The company had revenue of $92.82 million during the quarter, compared to the consensus estimate of $91.63 million. Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. Insmed's quarterly revenue was up 22.9% on a year-over-year basis. During the same period in the prior year, the company posted ($1.06) EPS. As a group, equities analysts anticipate that Insmed Incorporated will post -4.56 EPS for the current fiscal year.

Hedge Funds Weigh In On Insmed

Several institutional investors have recently bought and sold shares of INSM. Vanguard Group Inc. lifted its stake in shares of Insmed by 0.3% in the first quarter. Vanguard Group Inc. now owns 18,268,122 shares of the biopharmaceutical company's stock valued at $1,393,675,000 after buying an additional 49,149 shares during the period. Darwin Global Management Ltd. boosted its holdings in Insmed by 23.5% during the fourth quarter. Darwin Global Management Ltd. now owns 12,960,538 shares of the biopharmaceutical company's stock worth $894,796,000 after buying an additional 2,463,261 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in shares of Insmed by 1.7% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 12,923,541 shares of the biopharmaceutical company's stock valued at $985,938,000 after purchasing an additional 219,131 shares in the last quarter. Capital International Investors grew its position in Insmed by 9.1% in the fourth quarter. Capital International Investors now owns 7,116,997 shares of the biopharmaceutical company's stock valued at $491,357,000 after purchasing an additional 593,206 shares in the last quarter. Finally, Geode Capital Management LLC grew its position in shares of Insmed by 7.2% in the 4th quarter. Geode Capital Management LLC now owns 4,087,143 shares of the biopharmaceutical company's stock valued at $282,243,000 after acquiring an additional 273,759 shares during the period.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the company. UBS Group decreased their target price on Insmed from $110.00 to $109.00 and set a "buy" rating for the company in a research report on Friday, May 9th. Jefferies Financial Group assumed coverage on shares of Insmed in a research note on Tuesday, May 13th. They set a "buy" rating and a $105.00 price target on the stock. Royal Bank of Canada reaffirmed an "outperform" rating and set a $100.00 target price on shares of Insmed in a report on Wednesday, March 19th. Cantor Fitzgerald restated an "overweight" rating on shares of Insmed in a research report on Wednesday, February 19th. Finally, HC Wainwright reiterated a "buy" rating and set a $90.00 target price on shares of Insmed in a research report on Monday, May 12th. One equities research analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company's stock. According to data from MarketBeat, Insmed currently has an average rating of "Moderate Buy" and an average price target of $96.73.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.